Glooko reported growing clinical adoption of its EndoTool inpatient glycemic management solution, underscoring the company’s strengthening position in hospital-based diabetes care. A recent Scottsdale Institute webinar showcased how Corewell Health improved glycemic management after implementing EndoTool, despite initial clinician resistance to computer-guided dosing.
Within six months, clinicians developed a strong preference for the new workflow, highlighting the importance of earning clinician trust through user-friendly tools and integrated processes. Panelists from Corewell Health, Sharp HealthCare and Glooko emphasized that workflow integration and outcomes-focused design are central to driving durable clinical transformation in inpatient settings.
These developments support Glooko’s broader strategy of positioning its platform as a decision-support and intelligence layer in diabetes management, rather than a simple data aggregation tool. In its 2026 Global Diabetes Report, the company stresses that the value in digital diabetes care lies in extracting clear, actionable signals from large data volumes for clinicians.
The report highlights the need for tools that identify which patients require attention, when emerging risks appear and what patterns are hidden behind seemingly normal averages. By focusing on workflow-ready insights, Glooko aims to help providers better manage population-level glycemic control and align with value-based care initiatives.
If Glooko’s report continues to gain traction among health systems and payers, it could reinforce the company’s role as a thought leader in digital diabetes care and deepen customer engagement through tighter workflow integration. Together, the EndoTool adoption case study and the Global Diabetes Report point to a week of strategic validation for Glooko’s clinical and analytical capabilities, supporting its long-term growth prospects in the digital health market.